Skip to main content
SpringerLink
Log in

Alectinib/nivolumab

Erythema multiforme and increased levels of AST and ALT: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Nishiyama A, et al. Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review. [Review]. Internal Medicine 61: 1735-1738, No. 11, Jun 2022. Available from: URL: http://doi.org/10.2169/internalmedicine.7472-21

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib/nivolumab. Reactions Weekly 1912, 22 (2022). https://doi.org/10.1007/s40278-022-17725-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-17725-2

Search

Navigation